✦ LIBER ✦

Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary syndromes with a planned early invasive strategy

✍ Scribed by Philippe Gabriel Steg; Shamir R. Mehta; Charles V. Pollack Jr.; Christoph Bode; Christophe Gaudin; Karen Fanouillere; Angele Moryusef; Stephen D. Wiviott; Marc S. Sabatine

Book ID: 119183592
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 398 KB
Volume: 164
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2012.10.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Early Glycoprotein IIb/IIIa Inhibiti

The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale

✍ Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Design and rationale of CURRENT-OASIS 7:

Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non–ST-elevation acute coronary syndromes managed with an early invasive strategy

✍ Shamir R. Mehta; Jean-Pierre Bassand; Susan Chrolavicius; Rafael Diaz; Keith A.A 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 361 KB

Safety and Efficacy of Switching From Ei

Safety and Efficacy of Switching From Either Unfractionated Heparin or Enoxaparin to Bivalirudin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Managed With an Invasive Strategy: Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial

✍ Harvey D. White; Derek P. Chew; James W. Hoekstra; Chadwick D. Miller; Charles V 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 228 KB

Design and rationale of the MICHELANGELO

Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 758 KB

Randomized evaluation of the efficacy of

Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial

✍ David H. Fitchett; Anatoly Langer; Paul W. Armstrong; Mary Tan; Aurora Mendelsoh 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 142 KB

USEFULNESS OF BIOMARKERS FOR PROGNOSTICA

USEFULNESS OF BIOMARKERS FOR PROGNOSTICATION OF OUTCOME WITH EARLY INVASIVE OR NONINVASIVE TREATMENT IN NON-ST-ELEVATION ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL

✍ Lars Wallentin; Stefan James; Evangelos Giannitsis; Hugo Katus; Richard Becker; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 91 KB